Increased Plasma Visfatin Concentrations in Morbidly Obese Subjects Are Reduced after Gastric Banding
Dominik G. Haider,
Karin Schindler,
Georg Schaller,
Gerhard Prager,
Michael Wolzt and
Bernhard Ludvik
Departments of Clinical Pharmacology (D.G.H., G.S., M.W.) and Medicine III (K.S., M.W., B.L.), Division of Endocrinology and Metabolism, and Department of Surgery (G.P.), Division of General Surgery, Medical University of Vienna, 1090 Vienna, Austria
Address all correspondence and requests for reprints to: Bernhard Ludvik, M.D., Medical University of Vienna, Department of Internal Medicine III, Division of Endocrinology and Metabolism, Allgemeines Krankenhaus Wien, Währinger Gürtel 18-20, 1090 Vienna, Austria. E-mail: bernhard.ludvik{at}meduniwien.ac.at.
Context: The insulin-mimetic adipocytokine visfatin has beenlinked to obesity. The influence of weight loss on plasma visfatinconcentrations in obese subjects is unknown yet.
Objectives: In this study we investigated whether plasma visfatinconcentrations are altered by weight loss in patients with obesity.
Design and Patients: In a prospective study, fasting plasmavisfatin, leptin, and adiponectin concentrations were measuredbefore and 6 months after gastric banding in 31 morbidly obesepatients aged 40 ± 11 yr with a body mass index (BMI)of 46 ± 5 kg/m2. Fourteen healthy subjects aged 29 ±5 yr with a BMI less than 25 kg/m2 served as controls.
Results: Visfatin plasma concentrations were markedly elevatedin obese subjects (0.037 ± 0.008 µg/ml), comparedwith controls (0.001 ± 0.000 µg/ml, P < 0.001).Gastric banding reduced BMI to 40 ± 5 kg/m2, visfatinto 19.2 ± 10.9 ng/ml, and leptin from 39.0 ± 12.4to 29.7 ± 10.0 ng/ml and increased adiponectin from 0.015± 0.007 to 0.017 ± 0.007 µg/ml (all P <0.05) after 6 months. Insulin sensitivity as estimated by thehomeostasis model assessment insulin resistance index was unchangedfrom 5.8 ± 3.1 to 4.6 ± 1.9 (P = 0.13), but individualchanges of insulin resistance and visfatin were significantlyassociated (P < 0.05, r = –0.43).
Conclusions: Elevated plasma visfatin concentrations in morbidlyobese subjects are reduced after weight loss. This may be relatedto changes in insulin resistance over time.
This article has been cited by other articles:
O. M Ocon-Grove, S. M Krzysik-Walker, S. R Maddineni, G. L Hendricks III, and R. Ramachandran NAMPT (visfatin) in the chicken testis: influence of sexual maturation on cellular localization, plasma levels and gene and protein expression
Reproduction,
January 1, 2010;
139(1):
217 - 226.
[Abstract][Full Text][PDF]
K.-D. Nusken, M. Petrasch, M. Rauh, W. Stohr, E. Nusken, H. Schneider, and J. Dotsch Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol
Nephrol. Dial. Transplant.,
September 1, 2009;
24(9):
2832 - 2838.
[Abstract][Full Text][PDF]
J. F. de Boer, M. J. Bahr, K. H. W. Boker, M. P. Manns, and U. J. F. Tietge Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis
Am J Physiol Gastrointest Liver Physiol,
February 1, 2009;
296(2):
G196 - G201.
[Abstract][Full Text][PDF]
H. K. Song, M. H. Lee, B. K. Kim, Y. G. Park, G. J. Ko, Y. S. Kang, J. Y. Han, S. Y. Han, K. H. Han, H. K. Kim, et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy
Am J Physiol Renal Physiol,
November 1, 2008;
295(5):
F1485 - F1494.
[Abstract][Full Text][PDF]
N. Rasouli and P. A. Kern Adipocytokines and the Metabolic Complications of Obesity
J. Clin. Endocrinol. Metab.,
November 1, 2008;
93(11_Supplement_1):
s64 - s73.
[Abstract][Full Text][PDF]
J. E. Mallewa, E. Wilkins, J. Vilar, M. Mallewa, D. Doran, D. Back, and M. Pirmohamed HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options
J. Antimicrob. Chemother.,
October 1, 2008;
62(4):
648 - 660.
[Abstract][Full Text][PDF]
R. Adya, B. K. Tan, A. Punn, J. Chen, and H. S. Randeva Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis
Cardiovasc Res,
May 1, 2008;
78(2):
356 - 365.
[Abstract][Full Text][PDF]
S. M. Krzysik-Walker, O. M. Ocon-Grove, S. R. Maddineni, G. L. Hendricks III, and R. Ramachandran Is Visfatin an Adipokine or Myokine? Evidence for Greater Visfatin Expression in Skeletal Muscle than Visceral Fat in Chickens
Endocrinology,
April 1, 2008;
149(4):
1543 - 1550.
[Abstract][Full Text][PDF]
A. Korner, A. Garten, M. Bluher, R. Tauscher, J. Kratzsch, and W. Kiess Molecular Characteristics of Serum Visfatin and Differential Detection by Immunoassays
J. Clin. Endocrinol. Metab.,
December 1, 2007;
92(12):
4783 - 4791.
[Abstract][Full Text][PDF]
K M Choi, J H Kim, G J Cho, S H Baik, H S Park, and S M Kim Effect of exercise training on plasma visfatin and eotaxin levels
Eur. J. Endocrinol.,
October 1, 2007;
157(4):
437 - 442.
[Abstract][Full Text][PDF]
I. Kowalska, M. Straczkowski, A. Nikolajuk, A. Adamska, M. Karczewska-Kupczewska, E. Otziomek, S. Wolczynski, and M. Gorska Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome
Hum. Reprod.,
July 1, 2007;
22(7):
1824 - 1829.
[Abstract][Full Text][PDF]
D. G. Haider, A. Handisurya, A. Storka, E. Vojtassakova, A. Luger, G. Pacini, A. Tura, M. Wolzt, and A. Kautzky-Willer Visfatin Response to Glucose Is Reduced in Women With Gestational Diabetes Mellitus
Diabetes Care,
July 1, 2007;
30(7):
1889 - 1891.
[Full Text][PDF]
A. Malamitsi-Puchner, D. D. Briana, M. Boutsikou, E. Kouskouni, D. Hassiakos, and D. Gourgiotis Perinatal Circulating Visfatin Levels in Intrauterine Growth Restriction
Pediatrics,
June 1, 2007;
119(6):
e1314 - e1318.
[Abstract][Full Text][PDF]
E. Ingelsson, M. G. Larson, C. S. Fox, X. Yin, T. J. Wang, I. Lipinska, K. M. Pou, U. Hoffmann, E. J. Benjamin, J. F. Keaney Jr., et al. Clinical Correlates of Circulating Visfatin Levels in a Community-Based Sample
Diabetes Care,
May 1, 2007;
30(5):
1278 - 1280.
[Full Text][PDF]
G. Sun, J. Bishop, S. Khalili, S. Vasdev, V. Gill, D. Pace, D. Fitzpatrick, E. Randell, Y.-G. Xie, and H. Zhang Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men
Am. J. Clinical Nutrition,
February 1, 2007;
85(2):
399 - 404.
[Abstract][Full Text][PDF]
V. Varma, A. Yao-Borengasser, N. Rasouli, A. M. Bodles, B. Phanavanh, M.-J. Lee, T. Starks, L. M. Kern, H. J. Spencer III, R. E. McGehee Jr., et al. Human Visfatin Expression: Relationship to Insulin Sensitivity, Intramyocellular Lipids, and Inflammation
J. Clin. Endocrinol. Metab.,
February 1, 2007;
92(2):
666 - 672.
[Abstract][Full Text][PDF]
M. Manco, J. M. Fernandez-Real, F. Equitani, J. Vendrell, M. E. Valera Mora, G. Nanni, V. Tondolo, M. Calvani, W. Ricart, M. Castagneto, et al. Effect of Massive Weight Loss on Inflammatory Adipocytokines and the Innate Immune System in Morbidly Obese Women
J. Clin. Endocrinol. Metab.,
February 1, 2007;
92(2):
483 - 490.
[Abstract][Full Text][PDF]
B. K. Tan, J. Chen, J. E. Digby, S. D. Keay, C. R. Kennedy, and H. S. Randeva Increased Visfatin Messenger Ribonucleic Acid and Protein Levels in Adipose Tissue and Adipocytes in Women with Polycystic Ovary Syndrome: Parallel Increase in Plasma Visfatin
J. Clin. Endocrinol. Metab.,
December 1, 2006;
91(12):
5022 - 5028.
[Abstract][Full Text][PDF]
D. G. Haider, J. Pleiner, M. Francesconi, G. F. Wiesinger, M. Muller, and M. Wolzt Exercise Training Lowers Plasma Visfatin Concentrations in Patients with Type 1 Diabetes
J. Clin. Endocrinol. Metab.,
November 1, 2006;
91(11):
4702 - 4704.
[Abstract][Full Text][PDF]
A. Lopez-Bermejo, B. Chico-Julia, M. Fernandez-Balsells, M. Recasens, E. Esteve, R. Casamitjana, W. Ricart, and J.-M. Fernandez-Real Serum Visfatin Increases With Progressive {beta}-Cell Deterioration.
Diabetes,
October 1, 2006;
55(10):
2871 - 2875.
[Abstract][Full Text][PDF]
